lenalidomide has been researched along with epoetin alfa in 3 studies
| Studies (lenalidomide) | Trials (lenalidomide) | Recent Studies (post-2010) (lenalidomide) | Studies (epoetin alfa) | Trials (epoetin alfa) | Recent Studies (post-2010) (epoetin alfa) |
|---|---|---|---|---|---|
| 3,532 | 725 | 2,850 | 1,889 | 388 | 452 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (33.33) | 29.6817 |
| 2010's | 1 (33.33) | 24.3611 |
| 2020's | 1 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Cosler, LE; Ferro, SA; Greenberg, PL; Lyman, GH | 1 |
| Fenaux, P; Garcia-Manero, G | 1 |
| Altman, JK; Artz, AS; Bennett, JM; Cheema, PS; Claxton, DF; Komrokji, RS; List, AF; Litzow, MR; Luger, SM; Maciejewski, J; Mattison, RJ; McGraw, K; Schiffer, CA; Sun, Z; Tallman, MS; Verma, A; Wassenaar, TR | 1 |
1 review(s) available for lenalidomide and epoetin alfa
| Article | Year |
|---|---|
Hypomethylating agents and other novel strategies in myelodysplastic syndromes.
Topics: Antimetabolites, Antineoplastic; Azacitidine; Decitabine; DNA Methylation; Epoetin Alfa; Erythropoietin; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Lenalidomide; Myelodysplastic Syndromes; Prognosis; Recombinant Proteins; Thalidomide; Transplantation, Homologous | 2011 |
1 trial(s) available for lenalidomide and epoetin alfa
| Article | Year |
|---|---|
Lenalidomide-Epoetin Alfa Versus Lenalidomide Monotherapy in Myelodysplastic Syndromes Refractory to Recombinant Erythropoietin.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Drug Resistance, Neoplasm; Epoetin Alfa; Female; Follow-Up Studies; Humans; Lenalidomide; Male; Middle Aged; Myelodysplastic Syndromes; Neoplasm Recurrence, Local; Prognosis; Recombinant Proteins; Survival Rate | 2021 |
1 other study(ies) available for lenalidomide and epoetin alfa
| Article | Year |
|---|---|
The costs of drugs used to treat myelodysplastic syndromes following National Comprehensive Cancer Network Guidelines.
Topics: Anemia; Antineoplastic Agents; Azacitidine; Cost of Illness; Costs and Cost Analysis; Darbepoetin alfa; Decision Support Techniques; Deferoxamine; Drug Costs; Drug Therapy; Epoetin Alfa; Erythropoietin; Hematinics; Humans; Iron Chelating Agents; Lenalidomide; Myelodysplastic Syndromes; Practice Guidelines as Topic; Recombinant Proteins; Siderophores; Thalidomide; United States | 2008 |